利来国际

Be the most trusted biotech company

2026-08-21

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
2026-08-20

Comprehensive First-Line Coverage Across Advanced Lung Cancer, Henlius’ Serplulimab to Feature in Seven Studies at WCLC 2026
2026-08-20

WCLC 2026 Preview | HLX43, a Potential First PD-L1 ADC for TSCC, Shows Promising Efficacy with an ORR of 39.4% in Previously Treated Patients
2026-08-17

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
2026-08-11

Henlius Accelerates the New Landscape of Breast Cancer Treatment as HANQUYOU Marks Six Years Since Its Approval
2026-08-03

Henlius to Present Updated HLX43 TSCC Data and Seven Serplulimab Lung Cancer Studies at WCLC 2026, Addressing Unmet Needs
2026-07-31

Henlius Announces IND Approval for Its Innovative PD-L1 ADC HLX43 in Combination with Bevacizumab ± Chemotherapy
2026-07-30

Henlius' Announced First Patient Dosed for Its STEAP1×CD3×CD28 Tri-specific TCE HLX3902
2026-07-20

Henlius to Showcase 12 Research Presentations at ESMO 2026, Including U.S. Bridging Study of Serplulimab and POC of PD-L1 ADC HLX43 in Gastric Cancer